Imiloxan

Imiloxan

Imiloxan

Chemical compound

Imiloxan is a drug which is used in scientific research. It acts as a selective antagonist for the α2B adrenergic receptor,[1] and has been useful for distinguishing the actions of the different α2 adrenergic subtypes.[2][3]

Quick Facts Clinical data, ATC code ...

Synthesis

Imiloxan Synthesis:[4]

The imidazole portion of imiloxan is prepared by the reaction of an imidate with the diethyl acetal of aminoacetaldehyde. N-Alkylation of the imidazole with ethyl iodide gives imiloxan.

References

  1. [1]
    Michel AD, Loury DN, Whiting RL (March 1990). "Assessment of imiloxan as a selective alpha 2B-adrenoceptor antagonist". British Journal of Pharmacology. 99 (3): 560–4. doi:10.1111/j.1476-5381.1990.tb12968.x. PMC 1917331. PMID 1970500.
  2. [2]
    Cobos-Puc LE, Villalón CM, Sánchez-López A, Lozano-Cuenca J, Pertz HH, Görnemann T, Centurión D (January 2007). "Pharmacological evidence that alpha2A- and alpha2C-adrenoceptors mediate the inhibition of cardioaccelerator sympathetic outflow in pithed rats". European Journal of Pharmacology. 554 (2–3): 205–11. doi:10.1016/j.ejphar.2006.09.068. PMID 17109851.
  3. [3]
    Romero TR, de Castro Perez A, de Francischi JN, Gama Duarte ID (April 2009). "Probable involvement of alpha(2C)-adrenoceptor subtype and endogenous opioid peptides in the peripheral antinociceptive effect induced by xylazine". European Journal of Pharmacology. 608 (1–3): 23–7. doi:10.1016/j.ejphar.2009.02.019. PMID 19236861.
  4. [4]
    Caroon JM, Clark RD, Kluge AF, Olah R, Repke DB, Unger SH, et al. (June 1982). "Structure-activity relationships for 2-substituted imidazoles as alpha 2-adrenoceptor antagonists". Journal of Medicinal Chemistry. 25 (6): 666–70. doi:10.1021/jm00348a012. PMID 6124635.
  • Media related to Imiloxan at Wikimedia Commons
Stub icon

This antihypertensive-related article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Imiloxan, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.